<DOC>
	<DOCNO>NCT02072226</DOCNO>
	<brief_summary>PRISMS double-blind , multicenter , randomize , Phase IIIb study evaluate efficacy safety intravenous ( IV ) alteplase participant mild acute ischemic stroke appear clearly disable . Participants randomize 1:1 ratio receive within 3 hour last know well time either 1 ) one dose IV alteplase one dose oral aspirin placebo 2 ) one dose IV alteplase placebo one dose oral aspirin 325 milligram ( mg ) .</brief_summary>
	<brief_title>A Study Efficacy Safety Alteplase Participants With Mild Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Mild ischemic stroke define recent pretreatment NIHSS score less equal ( &lt; /= ) 5 determine clearly disable investigator Study treatment initiate within 3 hour last time participant see normal Computed tomography ( CT ) magnetic resonance imaging ( MRI ) find one following : 1 . CT clear large hypodensity great ( &gt; ) onethird middle cerebral artery ( MCA ) territory ( &gt; 100 cubic centimeter [ cc ] MCA territory ) 2 . MRI clear large hyperintensity concurrent diffusionweighted ( DW ) fluidattenuated inversion recovery ( FLAIR ) great onethird MCA territory ( great 100 cc MCA territory ) , 3 . Imaging lesion consistent acute hemorrhage , 4 . Evidence intraparenchymal tumor Disability prior present stroke Standard contraindication IV alteplase within 3 hour symptom onset , include : 1 . Head trauma , myocardial infarction , previous stroke within previous 3 month 2 . Gastrointestinal urinary tract hemorrhage within previous 21 day 3 . Major surgery within previous 14 day 4 . Arterial puncture noncompressible site within previous 7 day 5 . Any history ICH exception le ( &lt; ) 5 chronic microbleeds MRI 6 . Elevated blood pressure define systolic blood pressure &gt; 185 millimeter mercury ( mm Hg ) diastolic blood pressure &gt; 110 mm Hg , treatment require aggressive measure achieve acceptable level 7 . Treatment unfractioned heparin within past 48 hour activate partial thromboplastin time outside normal range 8 . Blood glucose &lt; 50 milligram per deciliter ( mg/dL ) 9. International normalized ratio &gt; 1.7 10 . Platelet count &lt; 100,000 per cubic millimeter ( /mm^3 ) 11 . Treatment direct thrombin inhibitor ( dabigatran ) factor Xa inhibitor ( apixaban , rivaroxaban , edoxaban ) within last 48 hour Allergic reaction study drug , aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) Females childbearing age know pregnant and/or lactate Inability swallow , would prevent oral intake aspirin aspirin placebo tablet Other serious , advanced , terminal illness would confound clinical outcome 90 day Current recent ( within 3 month ) participation another investigational drug treatment protocol Anticipated inability obtain 3month followup assessment Previous enrollment PRISMS Any condition deem investigator would pose hazard participant alteplase treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>